A CAPTIVATEing Analysis for Higher-Risk CLL.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37289004.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0807 and PMC identifier 10443675.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In an exploratory analysis of the phase II CAPTIVATE study, previously untreated patients with chronic lymphocytic leukemia with a higher-risk feature of immune globulin heavy chain variable (IGHV) unmutated status, del(17p), and/or TP53 mutation had similar efficacy and safety outcomes compared with patients without a higher-risk feature when treated with fixed-duration ibrutinib and venetoclax. See related article by Allan et al., p. 2593.
Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell